Understanding the Medicare Database Evidence on dHACM Cost-Effectiveness Research

In this video, Martha R. Kelso, RN, HBOT, touches on the extent of the evidence supporting a study on the cost-effectiveness of dHACM allografts in lower extremity diabetic ulcers.

This video is part 1 of a 3-part series of videos on dHACM allografts in lower extremity diabetic ulcers. For additional content, read the Advances article here.

Transcript:

Hi, thank you for inviting me. I'm excited to talk to you guys about this groundbreaking study. I'm Martha Kelso, I'm the CEO and founder for Wound Care Plus LLC. We're one of the Midwest's largest mobile wound companies that service a lot of the outpatient extended care facilities. Thanks for having me.

This particular allograft has some of the best clinical evidence on the market, and not biased evidence. When we look at all of the evidence together, this group has particularly studied with the most evidence, some of the larger cohort studies that are out there, and also non-biased information. That's important to me. So when we started looking at the Medicare database--obviously with the dehydrated human amnion chorion membrane, the dHACM membrane--we were actually able to see really great healing evidence as well looking at Medicare data. This is not a prospective study; we're not doing out own independent research. We're simply taking Medicare claims and reporting the data as found in the Medicare database. So it was super interesting to be a part of the study.